Motif Bio (MTFB) Receiving Somewhat Positive Media Coverage, Study Shows

News coverage about Motif Bio (NASDAQ:MTFB) has been trending somewhat positive on Sunday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Motif Bio earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.1880516518224 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several research analysts have issued reports on MTFB shares. WBB Securities started coverage on shares of Motif Bio in a research report on Friday, December 29th. They issued a “sell” rating and a $7.00 price target on the stock. ValuEngine upgraded shares of Motif Bio from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Seaport Global Securities restated a “buy” rating on shares of Motif Bio in a research report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $21.33.

Motif Bio (MTFB) opened at $9.90 on Friday. Motif Bio has a 12-month low of $5.80 and a 12-month high of $13.75.

TRADEMARK VIOLATION WARNING: “Motif Bio (MTFB) Receiving Somewhat Positive Media Coverage, Study Shows” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at

About Motif Bio

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Insider Buying and Selling by Quarter for Motif Bio (NASDAQ:MTFB)

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with's FREE daily email newsletter.

Leave a Reply